Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal vincristine in treating patients who have refractory or relapsed non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00006383

Run by

Inex Pharmaceuticals

Starts

2000-06-01

Expected to finish

2009-08-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• University of Illinois at Chicago — Chicago, Illinois, United States
• Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• University of Texas Health Center at Tyler — Tyler, Texas, United States
• Vermont Cancer Center — Burlington, Vermont, United States
• Tom Baker Cancer Center - Calgary — Calgary, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.